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Abstract 
 
Objectives: To investigate whether following a treat-to-target (T2T)-strategy in daily clinical 
practice leads to more patients with rheumatoid arthritis (RA) meeting the remission target.  
 
Methods: RA patients from 10 countries starting/changing conventional synthetic or biologic 
disease-modifying anti-rheumatic drugs were assessed for disease activity every 3 months for 
2 years (RA BIODAM cohort). Per visit was decided whether a patient was treated according 
to a T2T-strategy with DAS44 remission (DAS44<1.6) as the target. Sustained T2T was 
defined as T2T followed in 2 consecutive visits. The main outcome was the achievement of 
DAS44 remission at the subsequent 3-month visit. Other outcomes were remission according 
to DAS28-ESR, CDAI, SDAI and ACR/EULAR Boolean definitions. The association 
between T2T and remission was tested in generalized estimating equations models.  
  
Results: In total 4,356 visits of 571 patients [mean (SD) age: 56 (13) years, 78% female] 
were included. Appropriate application of T2T was found in 59% of the visits. T2T (vs no 
T2T) did not yield a higher likelihood of DAS44 remission 3 months later [OR (95%CI): 1.03 
(0.92;1.16)], but sustained T2T resulted in an increased likelihood of achieving DAS44 
remission [OR: 1.19 (1.03;1.39)]. Similar results were seen with DAS28-ESR remission. For 
more stringent definitions (CDAI, SDAI and ACR/EULAR Boolean remission), T2T was 
consistently positively associated with remission (OR range: 1.16-1.29), and sustained T2T 
had a more pronounced effect on remission (OR range: 1.49-1.52). 
 
Conclusion: In daily clinical practice, the correct application of a T2T-strategy (especially 
sustained T2T) in patients with RA leads to higher rates of remission.  
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Key messages (up to 5 bullet points): 
What is already known about this subject? 
 Randomized controlled trials have demonstrated the efficacy of treat-to-target approaches 
in rheumatoid arthritis.  Real life data from cohorts are still needed to support the 
widespread implementation of T2T in clinical practice. 
What does this study add? 
 In daily clinical practice, the correct application of a T2T-strategy in patients with RA 
leads to higher rates of remission as compared to not following it. 
 Not only in early RA, but also in established RA, following a T2T-strategy leads to 
higher remission rates. 
 
How might this impact on clinical practice or future developments? 
 Rheumatologists should be encouraged to follow a T2T-strategy to contribute to the 
achievement of higher rates of remission for their patients. 
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Introduction 
 
Early diagnosis, prompt commencement of disease modifying antirheumatic drug 
(DMARD) treatment and applying treat-to-target (T2T) strategies are now engrained 
in rheumatoid arthritis (RA) treatment paradigms. These approaches have 
substantially improved the outcomes of patients with RA.[1] Remission has been 
defined and agreed upon as the optimal target when managing a patient with RA.[2,3] 
Reaching the state of remission is associated with reduced radiographic progression 
and improved functional ability.[4] 
Thoroughly monitoring disease activity, adjusting treatment according to a fixed 
protocol and aiming at a predefined treatment goal, the so-called T2T-strategy, has 
advantages over usual care.[5,6] Several strategy studies provide the basis of this 
evidence, namely the TICORA (Tight Control of RA study)[7] and CAMERA 
(Computer Assisted Management in Early RA)[8] studies. Subsequently, several 
strategy studies have incorporated a T2T-strategy in their treatment algorithm in the 
formal comparison of specific therapies, such as was done in the BeSt (Behandel 
Strategiëen) study.[9] However, such evidence was gathered in the setting of 
randomized controlled trials (RCTs), with strict inclusion and exclusion criteria, 
following strict protocols and all particularities of RCTs. These studies provide the 
best evidence for the efficacy of T2T as an intervention, but to some extent 
compromise the generalizability of the findings, when one wants to consider applying 
them more broadly.  
Having formally demonstrated the efficacy of T2T in RCTs, it is important to assess 
whether this strategy also improves outcomes in unselected patients from daily 
clinical practice. The first cohort studies focused on patients with very early disease 
and confirmed that following a standardized intensive treatment led to improved 
achievement of remission.[10] Subsequently, some cohort studies have shown that 
tight-control treatment leads to more rapid remission and higher remission 
achievement after 1 or 2 years than usual care.[11,12] Nevertheless, the conclusions 
from these 2 studies were based on an indirect comparison between 2 different 
cohorts (one with T2T applied and another with usual care), with different patient 
characteristics, and focused on the remission achievement at 1 or 2 years in the 2 
cohorts. Such a comparison should ideally be made within the same cohort of 
patients, wherein some patients receive a T2T-strategy while others receive usual 
care. Real life data from cohorts without strict protocol specifications regarding 
choice of treatment are still needed to support the widespread implementation of T2T 
in clinical practice. Furthermore, previous studies have focused on the achievement of 
remission at a given time point, e.g. 1 or 2 years, ignoring whether or not the 
remission outcome was achieved in each of the visits throughout the follow-up (e.g. 3 
monthly visits, per T2T recommendations). A true longitudinal analysis taking all 
observations over time into account, both in terms of following T2T or not, and 
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achieving remission or not, reflecting daily clinically practice, has not yet been 
conducted. Additionally, T2T has not yet been investigated in patients with 
established RA. 
The aim of the present study was to investigate whether following a T2T-strategy 
leads to more patients with RA meeting the treatment target (remission) in daily 
clinical practice.  
 
Methods 
Study population 
Patients from RA BIODAM (BIOmarkers of joint DAMage), which has been 
previously described, were included.[13] In brief, RA BIODAM is a 2-year multi-
national prospective observational study, including patients with a clinical diagnosis 
of RA and also fulfilling the 2010 RA Classification Criteria,[14] recruited in daily 
practice from 10 countries from October 2011 to April 2015. To be eligible patients 
presented with active disease (44-joint disease activity score, DAS44>2.4)[15] and 
were to be started on or changing DMARD treatment, including conventional 
synthetic DMARDs (csDMARDs) and a first tumor necrosis factor inhibitor (TNFi); 
patients who had prior biologic (b)DMARD experience were excluded. All patients 
were included in this analysis. The database used for this analysis was locked in April 
2017. The study fulfilled Good Clinical Practice Guidelines, received ethical approval 
from the local ethics committees, and all patients provided informed consent. 
 
Remission 
Remission was the outcome of interest. According to the study protocol, patients were 
monitored every 3 months using DAS44 calculated with the erythrocyte 
sedimentation rate (ESR).[15] DAS44 remission, i.e. DAS44<1.6[16] was therefore 
chosen as the main outcome for this analysis. Alternative definitions of remission 
were also used, namely the 28-joint disease activity score[17] (DAS28-ESR) 
remission (i.e. DAS28-ESR<2.6),[18] the Clinical Disease Activity Index (CDAI) 
remission (i.e. CDAI 2.8),[19] the Simplified Disease Activity Index (SDAI) 
remission (SDAI 3.3),[20] and the American College of Rheumatology / European 
League Against Rheumatism (ACR/EULAR) Boolean remission (i.e. tender joint 
count (TJC) 1, swollen joint count (SJC) 1, C-reactive protein (CRP) 1mg/dL and 
patient global assessment (PGA) (0-10) 1).[2] All definitions of remission were 
binary (yes/no).  
 
Treat-to-target  
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Participating rheumatologists were required by protocol to follow a T2T-strategy with 
DAS44 remission (DAS44<1.6) as benchmark. In order to define whether a T2T-
strategy was appropriately followed or not, every visit was checked according to pre-
defined criteria. T2T was considered appropriate: i) if a patient had already a disease 
activity score below the target (DAS<1.6) and treatment was not intensified; or ii) if 
treatment was intensified upon a DAS≥1.6. Treatment intensification was defined as 
increasing dosage or adding a drug from the following categories: csDMARDs, 
bDMARDs or corticosteroids. T2T was considered incorrectly applied if: i) the target 
was met and treatment was nevertheless intensified; or ii) the target was not met and 
treatment was not intensified. 
Additional definitions for T2T were also considered for sensitivity analyses: i) T2T 
without corticosteroids, i.e. without considering corticosteroids as a treatment 
intensification; ii) T2T less strict, i.e. considering T2T as adequate as long as the 
target, DAS44 remission, is met, regardless of whether treatment is nevertheless 
intensified or not; iii) T2T-low disease activity (T2T-LDA) using LDA (i.e. 
DAS<2.4)[21] instead of remission as the benchmark. 
Furthermore, „sustained T2T‟ strategy was defined as following T2T in at least 2 
consecutive visits.  
 
Other relevant clinical information 
Age, gender, disease duration, rheumatoid factor (RF) and anti-citrullinated protein 
antibodies (ACPA) status (positive/negative) and being DMARD-naïve (yes vs no), 
all collected at baseline, were considered in this analysis as potential effect modifiers 
or confounders of the relationship of interest. Country of residence was also 
considered as a potential confounder. 
 
Statistical analysis 
The relationship between following T2T at a given visit and meeting the target of 
remission at the subsequent visit 3 months later was investigated using time-lagged 
generalized estimating equations (GEE) models. GEE is a suitable technique to make 
use of all available observations from each patient while adjusting for inherent within-
subject correlations of the repeated measurements. Models were time-lagged to allow 
investigation of the effect of the main predictor of interest (i.e. following T2T) on the 
outcome (i.e. remission) with a lag of 3 months; in other words, with the outcome 
occurring 3 months later. The same analyses were conducted to investigate the effect 
of sustained T2T on meeting the target of remission. The „exchangeable‟ working 
correlation structure, demonstrating the best fit to the data, was used. 
As treatment intensification has a central role in T2T, we sought to investigate the 
extent to which the components of the disease activity scores contributed to it. We 
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therefore investigated the effect of TJC>1, SJC>1, PGA>1 and CRP>1mg/dL on 
treatment intensification (yes/no). This analysis was also conducted with GEE, 
including all above-mentioned disease activity components in one multivariable 
model. 
For each model, interactions between the T2T variable and age, gender, disease 
duration and RF/ACP positivity were tested, and if significant (p<0.15) and clinically 
relevant the model was fitted in each subgroup. If these proved to be not relevant, 
final models were adjusted for potential confounders selected a priori: age, gender, 
disease duration and country of residence. Stata SE version 12 was used. 
 
Results  
 
In total, 571 patients were included with a mean age of 56 (SD 13) years, 78% 
females and a mean disease duration of 6.5 (8.0) years, 37% with a disease duration 
up to 2 years (Table 1). In total, 78% of the patients were RF and/or ACPA positive, 
and 48% were DMARD-naive at baseline (mean disease duration of 3.6 (5.6), 50% 
with 2-year disease duration). At the end of the baseline visit, almost 60% of the 
patients were on treatment with csDMARDs only, 35% of the patients on a TNFi with 
a csDMARD and only 6% on TNFi monotherapy. Almost half of the patients were on 
corticosteroids after the baseline visit.    
T2T was appropriately applied in 59% of 4,356 visits. This included 31% of patient 
visits where DAS44 remission was met and treatment was not intensified, and 28% of 
visits where treatment was appropriately escalated. In 3% of visits (9% of those with 
treatment intensification), treatment intensification took place even though DAS44 
remission was met (making a total of 31% of the visits with treatment intensification). 
In the remaining 38% of visits T2T was not being followed as there was no treatment 
intensification despite active disease (DAS44 1.6) (Figure 1).  
Throughout the 2-year follow-up period an increasing proportion of patients met 
remission definitions. At 3 months 24% of the patients were in DAS44 and DAS28-
ESR remission, and 8% in ACR/EULAR Boolean remission. At 24 months 52% of 
the patients were in DAS44 remission, also 52% in DAS28-ESR remission and 27% 
in ACR/EULAR Boolean remission (Figure 2).  
 
T2T on remission outcomes 
Following a T2T-strategy, as compared to not following it, was not significantly 
associated with a DAS44 or DAS28-ESR remission 3 months later (odds ratio (95% 
confidence interval) 1.03 (0.92; 1.16) and 1.03 (0.91; 1.16), respectively), but was 
significantly associated with ACR/EULAR Boolean remission (OR 1.16 (1.01; 1.34)) 
and also with CDAI remission (OR 1.29 (1.12; 1.49)) and SDAI remission (OR 1.24 
(1.08; 1.41)) (Table 2). Results of the sensitivity analyses were similar, except for a 
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slightly stronger association between T2T and remission outcomes for both „T2T 
without corticosteroids‟ and „T2T-REM less strict‟. With T2T-LDA, with LDA as the 
benchmark, there was a significant association between T2T and all remission 
outcomes (OR between 1.3 and 1.4). None of the tested effect modifiers, namely age, 
gender, disease duration, seropositivity or DMARD naïve (vs not), modified the 
relationships of interest. 
 
 
Sustained T2T on remission outcomes 
Following a sustained T2T-strategy compared to not following it was associated with 
remission 3 months later according to all definitions, e.g. DAS44 remission OR 1.19 
(1.03; 1.39) or ACR/EULAR Boolean remission (OR 1.49 (1.24;1.81)) (Table 3). 
 
Relationship between disease activity components and treatment intensification 
All disease activity components were significantly associated with treatment 
intensification, with SJC and TJC showing the strongest associations, also in a 
multivariable model including all the components: OR „SJC>1‟ 3.42 (2.89; 4.05), OR 
„TJC>1‟ 3.35 (2.72; 4.11), OR „PGA>1‟ 2.14 (1.71; 2.68) and OR „CRP>1‟ 2.00 
(1.66; 2.42). 
 
Discussion 
In the present study we have shown that following a T2T-strategy, and particularly 
sustained T2T, in daily clinical practice leads to more patients with RA meeting the 
most stringent remission criteria over time. This is the first comprehensive analysis 
that considers all available visits of unselected patients who were followed by 
protocol for a period of 2 years. The results of the analysis provide direct evidence 
that following T2T, and particularly sustained T2T, immediately results in a higher 
likelihood of remission at the next visit, 3 months later (the longitudinal interpretation 
of a T2T-strategy). Moreover, we have for the first time shown that following T2T is 
also efficacious in patients with established RA, while previous studies focused on the 
effect of T2T in patients with early RA. 
The strictly temporal relationship between following a T2T-strategy and meeting 
remission was statistically significant for almost all remission outcomes and for the 
different T2T definitions used. The exceptions were the DAS44 and DAS28-ESR 
remission definitions with an interval of 3 months only, while for sustained T2T the 
relationship with all remission outcomes was statistically significant. The explanation 
is rather technical: the independent variable (T2T with DAS44 as benchmark) and the 
outcome (i.e. DAS44 remission) include exactly the same disease activity score, 
which implies that the model becomes inherently auto-regressive. Such a scenario 
effectively removes the variability in the data necessary to demonstrate efficacy of an 
intervention.  The other definitions of remission are slightly different from the 
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benchmark definition and allow more statistical separation. An alternative explanation 
is that DAS44 and DAS28-ESR definitions are more lenient in comparison to 
ACR/EULAR Boolean, CDAI, and SDAI remission and are more frequently met even 
if T2T is not applied.[2] Nevertheless, the signal that a T2T-strategy, and particularly 
sustained T2T-strategy, increases the likelihood of stringent remission is clear and 
consistent. Also, these findings became even more evident throughout the follow-up 
of this study. The proportion of patients achieving remission, regardless of its 
definition, increased substantially through follow-up (Figure 2).  Even after 2 years, a 
plateau has not yet been reached, reassuring clinicians that if we measure disease 
activity and treat patients effectively over time, high remission rates can be achieved.  
These findings come from a population of patients with an average of 6.5 years of 
disease duration. One may speculate that the effect of following T2T could be even 
better in early disease. In this study, we have not found any differences between 
patients DMARD naïve vs not and also according to disease duration, but a lack of 
statistical power cannot be excluded. Additionally, even patients who were DMARD 
naïve had a relatively long disease duration (average of 3.6 years), not being the most 
representative DMARD naïve patients.  
If T2T is so clearly associated with clinical remission, as shown here and in the 
literature, [5,6] why, then, is a T2T-strategy not always followed in clinical practice? 
Even in this study, with a protocol requiring implementation of T2T, this strategy was 
„only‟ followed in less than two thirds of the visits. Also within the RA BIODAM 
cohort, we have shown that, among other factors, the absence of objective signs of 
inflammation (e.g. swollen joints) implied a lower likelihood to follow T2T.[22] Also, 
in the 10-year follow-up of the BeSt trial, non-adherence to the protocol has been 
assigned to disagreement with how DAS reflects disease activity (felt to overestimate 
the real disease activity) and disagreement with the subsequently required step in the 
protocol.[23] Many clinicians find regularly measuring disease activity too time 
consuming endeavour and consider it an additional barrier to implementation of 
T2T.[24,25]  
In order to launch new strategies or interventions in clinical practice, the formulation 
of recommendations, like the T2T recommendations,[27] does not suffice, and 
implementation should actively be promoted. Studies like ours may further 
corroborate the message that T2T leads to more stringent remission and may help 
implementation in clinical practice. Appropriate education may also help. The 
intervention of the TRACTION trial included one educational face-to-face meeting 
and monthly webinars on the principles and practical advice on implementation of 
T2T. A substantial improvement in the adherence to T2T was demonstrated with 
improvement of 46% in the arm following the training program compared to 14% in 
the control arm.[28] Still,  rheumatologists may report compliance with 
recommendations but in practice do not always follow them.[29] 
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Some limitations of this study need to be considered. First, it is designed as an 
observational study reflecting daily clinical practice with unselected patients 
contrasting with the reality of RCTs from which most evidence on T2T originates to 
date. However, one may question how close to daily clinical practice the RA 
BIODAM cohort really is, with participation from only a few centers per country, 
several being tertiary referral centers, and with rheumatologists mandated to follow a 
strict T2T protocol. As in principle, rheumatologists were required to follow T2T per 
protocol, we have in this study in essence compared the visits in which the protocol 
was followed to others in which protocol was violated. One can therefore not exclude 
a bias intrinsic to this comparison. Additionally, detailed reasons for not following 
T2T have not been adequately registered precluding additional analysis of adherence 
to T2T versus taking the physician‟s reasoning into account. Moreover, only patients 
with active disease were included, and the average baseline disease activity was high. 
This may preclude the generalizability of the findings to patients with low disease 
activity, and not answer the question of whether following a T2T-strategy is 
beneficial in patients already in low disease activity, given the risks of 
overtreatment.[30,31] Lastly, when investigating the impact of following a T2T-
strategy, one is not only analysing the impact of treatment intensification but 
implicitly one is evaluating visits in which patients are already in remission, which 
have accentuated the benefit of T2T. However, it was our aim to investigate the 
impact of following the T2T-strategy in its whole and not parts of it, as well as to take 
all disease activity measurements into account as the longitudinal technique chosen 
properly does. As a main strength, this is a multinational observational study, 
including unselected patients reflecting daily clinical practice, with the first truly 
longitudinal analysis addressing the impact of following a (sustained) T2T-strategy. 
In conclusion, following a T2T-strategy, and especially sustained T2T, works in daily 
clinical practice and leads to more patients meeting the target, i.e. remission. 
Rheumatologists should be encouraged to follow a T2T-strategy to contribute to the 
achievement of higher rates of remission for their patients. 
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Table 1 - Baseline characteristics  
 N = 571 
Mean (SD) or n 
(%) 
Age, years 55.7 (12.9) 
Female gender 434 (76.0%) 
Disease duration, years 6.5 (8.0) 
Education, years 12.6 (3.8) 
Number of comorbidities 1.2 (1.3) 
Rheumatoid factor positivity 370 (68.0%) 
Anti-CCP positivity 388 (69.3%) 
RF and/or anti-CCP positivity 431 (77.7%) 
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DAS44 (0-10) 3.8 (1.0) 
DAS28-ESR (0-10) 5.2 (1.2) 
CDAI (0-76) 26.9 (11.6) 
SDAI (0-86) 28.5 (12.4) 
Patient global (0-10) 5.7 (2.3) 
HAQ (0-3) 1.1 (0.7) 
SJC (0-44) 8.4 (6.1) 
TJC (0-53) 13.6 (9.1) 
ESR (mm/h) 28.7 (22.2) 
CRP (mg/dL) 1.5 (2.3) 
Number of prior DMARDs 0.9 (1.1) 
DMARD naïve 274 (48.0%) 
Smoking status  
- Never smoker 282 (49.4%) 
- Current smoker 161 (28.2%) 
- Ex-smoker 128 (22.4%) 
Treatment csDMARD/TNFi started at 
baseline 
 
- Both 196 (34.6%) 
- csDMARD only 334 (58.9%) 
- TNFi only 36 (6.3%) 
- None 1 (0.2%) 
Treatment with oral corticosteroids started at 
baseline 
255 (45%) 
Anti-CCP: anti-citrullinated protein; RF: rheumatoid factor; DAS44: 44-joint 
disease activity score; DAS28-ESR: 28-joint disease activity score (with 
erythrocyte sedimentation rate); CDAI: Clinical Disease Activity Index; SDAI: 
Simple Disease Activity Index; HAQ: health assessment questionnaire; SJC: 
swollen joint count; TJC: tender joint count; ESR: erythrocyte sedimentation 
rate; CRP: C-reactive protein; DMARD: disease modifying anti-rheumatic 
drug; csDMARD: conventional synthetic disease modifying anti-rheumatic 
drug; TNFi: tumor necrosis factor inhibitor
  
 
 
 
 
Figure 1 - Proportion of the visits (n = 4,356) in which treat-to-target strategy (with DAS44<1.6 as benchmark) is followed vs not and the 
details regarding the proportion of visits with target achievement and/or treatment intensification. Treatment intensification was defined as 
start or dosage increase of a conventional synthetic or biological disease modifying antirheumatic drug or of a corticosteroid. 
DAS44: 44-joint disease activity score 
 
 
 
 
 
Figure 2 – Proportion of achievement of the different remission outcomes throughout the 2-year follow-
up. DAS44: 44-joint disease activity score; DAS28-ESR: 28-joint disease activity score; ACR: American 
College of Rheumatology; EULAR: European League Against Rheumatism; CDAI: Clinical Disease 
Activity Index; SDAI: Simple Disease Activity Index
 Table 2 – Effect of following treat-to-target strategies on remission outcomes 3 months later* 
 
DAS44 
remission 
(OR (95% CI)) 
DAS28-ESR 
remission 
(OR (95% CI)) 
ACR/EULAR 
Boolean remission 
(OR (95% CI)) 
CDAI remission 
(OR (95% CI)) 
SDAI remission 
(OR (95% CI)) 
T2T 1.03 (0.92; 1.16) 1.03 (0.91; 1.16) 1.16 (1.01; 1.34) 1.29 (1.12; 1.49) 1.24 (1.08; 1.41) 
T2T without corticosteroids 1.07 (0.95; 1.20) 1.11 (0.98; 1.26) 1.23 (1.06; 1.42) 1.37 (1.18; 1.59) 1.34 (1.17; 1.53) 
T2T-REM less strict 1.06 (0.94; 1.19) 1.07 (0.95; 1.21) 1.32 (1.13; 1.53) 1.43 (1.22; 1.67) 1.34 (1.17; 1.54) 
T2T-LDA 1.26 (1.10; 1.44) 1.36 (1.17; 1.56) 1.27 (1.09; 1.47) 1.39 (1.18; 1.64) 1.36 (1.17; 1.59) 
* All models adjusted for age, gender, disease duration and country. T2T was considered being followed: i) if a patient had already a disease activity score 
below the target (DAS<1.6; DAS<2.4 for LDA definition) and treatment was correctly not intensified; or ii) if treatment was intensified upon a DAS≥1.6 (or 
DAS ≥2.4 for LDA definition). T2T without corticosteroids: without considering corticosteroids in treatment intensification. T2T-REM less strict: considering 
T2T as adequate as long as the target, DAS44 remission, is met, regardless of whether treatment nevertheless intensified or not. T2T: treat-to-target; LDA: low 
disease activity; DAS44: 44-joint disease activity score; DAS28-ESR: 28-joint disease activity score; ACR: American College of Rheumatology; EULAR: 
European League Against Rheumatism; CDAI: Clinical Disease Activity Index; SDAI: Simple Disease Activity Index; OR: odds ratio; CI: confidence interval. 
 
 
Table 3 - Effect of following a sustained treat-to-target strategy on remission outcomes 3 months later* 
 DAS44 sustained 
remission 
(OR (95% CI)) 
DAS28-ESR 
sustained remission 
(OR (95% CI)) 
ACR/EULAR 
Boolean sustained 
remission 
(OR (95% CI)) 
CDAI sustained 
remission 
(OR (95% CI)) 
SDAI sustained 
remission 
(OR (95% CI)) 
Sustained T2T 1.19 (1.03; 1.39) 1.23 (1.06; 1.44) 1.49 (1.24; 1.81) 1.45 (1.19; 1.77) 1.52 (1.27; 1.82) 
* All models adjusted for age, gender, disease duration and country. Sustained treat-to-target was considered followed if T2T was followed in ≥2 subsequent 
visits. T2T was considered being followed: i) if a patient had already a disease activity score below the target (DAS<1.6; DAS<2.4 for LDA definition) and 
treatment was correctly not intensified; or ii) if treatment was intensified upon a DAS≥1.6 (or DAS ≥2.4 for LDA definition). T2T: treat-to-target; DAS44: 44-
joint disease activity score; DAS28-ESR: 28-joint disease activity score; ACR: American College of Rheumatology; EULAR: European League Against 
Rheumatism; CDAI: Clinical Disease Activity Index; SDAI: Simple Disease Activity Index; OR: odds ratio; CI: confidence interval.
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